Bital Savir-Baruch

Bital Savir-Baruch

Radiology | Nuclear Medicine

1625 North Campbell Avenue
Tucson, AZ 85719

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 15, 2026

Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals.

Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 31, 2025

Index Hepatic Decompensation: Hepatic Hydrothorax Without Signs of Clinically Significant Portal Hypertension Diagnosed With Radioisotope Scintigraphy.

Index Hepatic Decompensation: Hepatic Hydrothorax Without Signs of Clinically Significant Portal Hypertension Diagnosed With Radioisotope Scintigraphy.

Journal: ACG case reports journal

Published: February 16, 2025

Beyond the AJR: PET/MRI Using 68Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients With Biochemical Failure After Prostate Cancer Treatment.

Beyond the AJR: PET/MRI Using 68Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients With Biochemical Failure After Prostate Cancer Treatment.

Journal: AJR. American journal of roentgenology

Published: May 15, 2024

Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance.

Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance.

Journal: Nuclear medicine communications

Published: April 11, 2023

Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.

Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.

Journal: Urologic oncology

Published: January 13, 2023

Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer.

Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer.

Journal: Molecular imaging and biology

Published: December 11, 2022

Prostate Cancer Imaging with 18F-Fluciclovine.

Prostate Cancer Imaging with 18F-Fluciclovine.

Journal: PET clinics

Published: October 13, 2022

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

Journal: Clinical nuclear medicine

Published: May 04, 2022

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

Journal: American journal of clinical oncology

Published: May 04, 2022

177Lu-PSMA Therapy.

177Lu-PSMA Therapy.

Journal: Journal of nuclear medicine technology

Published: March 31, 2022

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 21, 2021

Showing 1-12 of 41

Last Updated: 09/26/2026